SCHEMBL6035149

SCHEMBL6035149

CCOc1ccc(CC#N)cc1OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
ATM Q13315 1/20 0.56
MAPT P10636 3/20 0.52
POLB P06746 1/20 0.52
THRB P10828 1/20 0.52
LMNA P02545 2/20 0.51
KDM4E B2RXH2 2/20 0.51
HTR1A P08908 2/20 0.50
ADRA1D P25100 2/20 0.50
ADRA1A P35348 2/20 0.50
ADRA1B P35368 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.47
GAA P10253 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 2/20 0.47
MRGPRX4 Q96LA9 1/20 0.47
HSD17B10 Q99714 2/20 0.46
APP P05067 1/20 0.45
MAPK1 P28482 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1465482 0.93 SLC2A1 (0.49) MEN1KMT2AATMMAPTKDM4E
SCHEMBL2967916 0.88 CALM1 (0.45) MEN1KMT2AMAPTPOLBLMNA
SCHEMBL30028270 0.87 MEN1 (0.56) MEN1KMT2AMAPTLMNAKDM4E
SCHEMBL1464842 0.87 MAPK1 (0.55) MEN1KMT2AMAPTLMNAKDM4E
SCHEMBL6355596 0.87 MEN1 (0.56) MEN1KMT2AMAPTLMNAKDM4E
SCHEMBL31040288 0.83 MEN1 (0.47) MEN1KMT2AMAPTLMNAKDM4E
SCHEMBL31040282 0.83 MEN1 (0.47) MEN1KMT2AMAPTLMNAKDM4E
SCHEMBL30028244 0.83 MEN1 (0.47) MEN1KMT2AMAPTLMNAKDM4E
SCHEMBL12251449 0.83 MEN1 (0.63) MEN1KMT2AATMMAPTPOLB
SCHEMBL2391409 0.83 MAPK1 (0.41) MEN1KMT2AATMMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 MEN1 2048/4885KMT2A 1706/4885ATM 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.